Live Markets »News & Advice»Market News»Market News Details
Market News Details

Lupin's pneumonia drug Atovaquone oral suspension receives USFDA approval

Press Trust of India/New Delhi 12 Sep 18 | 04:30 PM

Representative Image

Drug firm Lupin on Wednesday said it has received nod from the US health regulator to market its Atovaquone oral suspension used for prevention and treatment of a type of pneumonia.

Related Stories

    No Related Stories Found
Widgets Magazine

The company has received approval to market generic Atovaquone oral suspension USP in the strength of 750 mg/5 mL from the United States Food and Drug Administration (USFDA), Lupin said in a BSE filing.

The product is a generic version of GlaxoSmithKline LLC's Mepron oral suspension in the same strength, it added.

As per IQVIA MAT June 2018 data, Atovaquone oral suspension, 750 mg/5 mL had annual sales of around $117.4 million in the US, Lupin said.

The product is "indicated for prevention and acute oral treatment of mild-to moderate pneumocystis carinii pneumonia (PCP) in patients intolerant to trimethoprim-sulfamethoxazole," it added.

Shares of Lupin Ltd on Wednesday closed at Rs 956.35 per scrip on BSE, up 1.78 per cent from its previous close.

Widgets Magazine


Company Price Gain (%)
Yes Bank103.9011.48
Tata Motors169.855.53
Sun Pharma.Inds.433.252.57
Power Grid Corpn209.002.05


Currently No Poll Available.

Online Portfolio

You can create Online Portfolio here using the below button.

Widgets Magazine